The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro

Journal of Clinical Endocrinology and Metabolism

Volumn 89, Issue 4, 2004, Pages 1577-1585

  Hofland, Leo J ^a   Van Der Hoek, Joost ^a   Van Koetsveld, Peter M ^a   De Herder, Wouter W ^a   Waaijers, Marlijn ^a   Sprij Mooij, Diana ^a   Bruns, Christian ^b   Weckbecker, Gisbert ^b   Feelders, Richard ^a   Van Der Lely, Aart Jan ^a   Beckers, Albert ^c   Lamberts, Steven W J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b NOVARTIS PHARMA AG   (Switzerland)

^c UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; MESSENGER RNA; OCTREOTIDE; PASIREOTIDE; PROLACTIN; SOMATOSTATIN 14; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 5; SRIF 14; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BINDING AFFINITY; CELL CULTURE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; FEMALE; GROWTH HORMONE RELEASE; HUMAN; HUMAN CELL; HYPOPHYSIS ADENOMA; IC 50; MALE; PRIORITY JOURNAL; PROLACTIN RELEASE; PROLACTINOMA; PROTEIN EXPRESSION;

ADENOMA; ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HORMONE ANTAGONISTS; HUMAN GROWTH HORMONE; HUMANS; MALE; MIDDLE AGED; OCTREOTIDE; PITUITARY NEOPLASMS; PROLACTIN; PROTEIN ISOFORMS; RECEPTORS, SOMATOSTATIN; RNA, MESSENGER; SOMATOSTATIN; TUMOR CELLS, CULTURED;

EID: 11144353578     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2003-031344     Document Type: Article

References (33)

1. Freda PU 2002 Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 87:3013-3018
2. Shimon I, Taylor JE, Dong JZ, Bitonte RA, Kim S, Morgan B, Coy DH, Culler MD, Melmed S 1997 Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation. J Clin Invest 99: 789-798
3. Greenman Y, Melmed S 1994 Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage. J Clin Endocrinol Metab 79:724-729
4. Greenman Y, Melmed S 1994 Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors. J Clin Endocrinol Metab 78:398-403
5. Nielsen S, Mellemkjaer S, Rasmussen LM, Ledet T, Astrup J, Weeke J, Jorgensen JO 1998 Gene transcription of receptors for growth hormone-releasing peptide and somatostatin in human pituitary adenomas. J Clin Endocrinol Metab 83:2997-3000
6. Panetta R, Patel YC 1995 Expression of mRNA for all five human somatostatin receptors (hSSTR1-5) in pituitary tumors. Life Sci 56:333-342
7. Murabe H, Shimatsu A, Ihara C, Mizuta H, Nakamura Y, Nagata I, Kikuchi H, Nakao K 1996 Expression of somatostatin receptor (SSTR) subtypes in pituitary adenomas: quantitative analysis of SSTR2 mRNA by reverse transcription- polymerase chain reaction. J Neuroendocrinol 8:605-610
8. Miller GM, Alexander JM, Bikkal HA, Katznelson L, Zervas NT, Klibanski A 1995 Somatostatin receptor subtype gene expression in pituitary adenomas. J Clin Endocrinol Metab 80:1386-1392
9. Jaquet P, Saveanu A, Gunz G, Fina F, Zamora AJ, Grino M, Culler MD, Moreau JP, Enjalbert A, Ouafik LH 2000 Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes. J Clin Endocrinol Metab 85:781-792
10. Saveanu A, Gunz G, Dufour H, Caron P, Fina F, Ouafik L, Culler MD, Moreau JP, Enjalbert A, Jaquet P 2001 Bim-23244, a somatostatin receptor subtype 2-and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas. J Clin Endocrinol Metab 86:140-145
11. Shimon I, Yan X, Taylor JE, Weiss MH, Culler MD, Melmed S 1997 Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. J Clin Invest 100:2386-2392
12. Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G 2002 SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 146:707-716
13. Weckbecker G, Briner U, Lewis I, Bruns C 2002 SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs. Endocrinology 143: 4123-4130
14. Jaquet P, Ouafik L, Saveanu A, Gunz G, Fina F, Dufour H, Culler MD, Moreau JP, Enjalbert A 1999 Quantitative and functional expression of somatostatin receptor subtypes in human prolactinomas. J Clin Endocrinol Metab 84:3268-3276
15. Oosterom R, Blaauw G, Singh R, Verleun T, Lamberts SW 1984 Isolation of large numbers of dispersed human pituitary adenoma cells obtained by aspiration. J Endocrinol Invest 7:307-311
16. Ferone D, Pivonello R, Van Hagen PM, Dalm VA, Lichtenauer-Kaligis EG, Waaijers M, Van Koetsveld PM, Mooy DM, Colao A, Minuto F, Lamberts SW, Hofland LJ 2002 Quantitative and functional expression of somatostatin receptor subtypes in human thymocytes. Am J Physiol Endocrinol Metab 283:E1056-E1066
17. Lamberts SW, Verleun T, Hofland L, Del Pozo E 1987 A comparison between the effects of SMS 201-995, bromocriptine and a combination of both drugs on hormone release by the cultured pituitary tumour cells of acromegalic patients. Clin Endocrinol (Oxf) 27:11-23
18. Hofland LJ, Velkeniers B, vd Lely AJ, van Koetsveld PM, Kazemzadeh M, Waaijers M, Hooghe-Peters EL, Lamberts SW 1992 Long-term in vitro treatment of human growth hormone (GH)-secreting pituitary adenoma cells with octreotide causes accumulation of intracellular GH and GH mRNA levels. Clin Endocrinol (Oxf) 37:240-248
19. Lamberts SW 1988 The role of somatostatin in the regulation of anterior pituitary hormone secretion and the use of its analogs in the treatment of human pituitary tumors. Endocr Rev 9:417-436
20. Lamberts SW, Hofland LJ, de Herder WW, Kwekkeboom DJ, Reubi JC, Krenning EP 1993 Octreotide and related somatostatin analogs in the diagnosis and treatment of pituitary disease and somatostatin receptor scintigraphy. Front Neuroendocrinol 14:27-55
21. Rocheville M, Lange DC, Kumar U, Sasi R, Patel RC, Patel YC 2000 Subtypes of the somatostatin receptor assemble as functional homo-and heterodimers. J Biol Chem 275:7862-7869
22. Patel RC, Kumar U, Lamb DC, Eid JS, Rocheville M, Grant M, Rani A, Hazlett T, Patel SC, Gratton E, Patel YC 2002 Ligand binding to somatostatin receptors induces receptor-specific oligomer formation in live cells. Proc Natl Acad Sci USA 99:3294-3299
23. Ren SG, Taylor J, Dong J, Yu R, Culler MD, Melmed S 2003 Functional association of somatostatin receptor subtypes 2 and 5 in inhibiting human growth hormone secretion. J Clin Endocrinol Metab 88:4239-4245
24. Lewis I, Bauer W, Albert R, Chandramouli N, Pless J, Weckbecker G, Bruns C 2003 A novel somatostatin mimic with broad somatotropin release inhibitory factor receptor binding and superior therapeutic potential. J Med Chem 46: 2334-2344
25. Melmed S, Braunstein GD, Horvath E, Ezrin C, Kovacs K 1983 Pathophysiology of acromegaly. Endocr Rev 4:271-290
26. Zatelli MC, Piccin D, Tagliati F, Ambrosio MR, Margutti A, Padovani R, Scanarini M, Culler MD, degli Uberti EC 2003 Somatostatin receptor subtype 1 selective activation in human growth hormone (GH)-and prolactin (PRL)-secreting pituitary adenomas: effects on cell viability, GH, and PRL secretion. J Clin Endocrinol Metab 88:2797-2802
27. Colao A, di Sarno A, Pivonello R, di Somma C, Lombardi G 2002 Dopamine receptor agonists for treating prolactinomas. Expert Opin Investig Drugs 11: 787-800
28. Webster J 1999 Clinical management of prolactinomas. Baillieres Best Pract Res Clin Endocrinol Metab 13:395-408
29. Ferjoux G, Bousquet C, Cordelier P, Benali N, Lopez F, Rochaix P, Buscail L, Susini C 2000 Signal transduction of somatostatin receptors negatively controlling cell proliferation. J Physiol Paris 94:205-210
30. Ballare E, Persani L, Lania AG, Filopanti M, Giammona E, Corbetta S, Mantovani S, Arosio M, Beck-Peccoz P, Faglia G, Spada A 2001 Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somatostatin analog treatment. J Clin Endocrinol Metab 86: 3809-3814
31. Lamberts SW, Uitterlinden P, del Pozo E 1987 SMS 201-995 induces a continuous decline in circulating growth hormone and somatomedin-C levels during therapy of acromegalic patients for over two years. J Clin Endocrinol Metab 65:703-710
32. van der Hoek J, de Herder WW, Feelders RA, van der Lely A-J, Uitterlinden P, Boerlin V, Bruns C, Poon KW, Lewis I, Weckbecker G, Krahnke T, Hofland LJ, Lamberts SW 2004 A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients. J Clin Endocrinol Metab 89:638-645
33. Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ 1996 Octreotide. N Engl J Med 334:246-254